Skip to content

PTHS PTHS Deferred offering costs

Deferred offering costs at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$164.72K
Hitachi logo
HitachiHIT
$170.98K
NextNRG, Inc. Common Stock logo
NextNRG, Inc. Common StockNXXT
$18.09K-98.8%
Bain Capital Specialty Finance logo
Bain Capital Specialty FinanceBCSF
$3.29M-24.2%
IRA
Iris Acquisition IRAB
$0
DeFi Development Corp. Common Stock logo
DeFi Development Corp. Common StockDFDV
$3.36M+2,861%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:DeferredOfferingCosts.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's deferred offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's deferred offering costs?
PTHS (PTHS) reported deferred offering costs of $711K in Q1 2026.
How has PTHS's deferred offering costs changed year-over-year?
PTHS's deferred offering costs decreased by 1.7% year-over-year, from $723.13K to $711K.